TY - JOUR
T1 - Trace Amine-Associated Receptor 1 (TAAR1)
T2 - Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities
AU - Nair, Pramod C.
AU - Chalker, Justin M.
AU - McKinnon, Ross A.
AU - Langmead, Christopher J.
AU - Gregory, Karen J.
AU - Bastiampillai, Tarun
PY - 2022/3/11
Y1 - 2022/3/11
N2 - Schizophrenia is a complex and severe mental illness. Current treatments for schizophrenia typically modulate dopaminergic neurotransmission by D2-receptor blockade. While reducing positive symptoms of schizophrenia, current antipsychotic drugs have little clinical effect on negative symptoms and cognitive impairments. For the last few decades, discovery efforts have sought nondopaminergic compounds with the aim to effectively treat the broad symptoms of schizophrenia. In this viewpoint, we provide an overview on trace-amine associated receptor-1 (TAAR1), which presents a clinically validated nondopaminergic target for treating schizophrenia and related disorders, with significantly less overall side-effect burden. TAAR1 agonists may also be specifically beneficial for the substance abuse comorbidity and metabolic syndrome that is often present in patients with schizophrenia.
AB - Schizophrenia is a complex and severe mental illness. Current treatments for schizophrenia typically modulate dopaminergic neurotransmission by D2-receptor blockade. While reducing positive symptoms of schizophrenia, current antipsychotic drugs have little clinical effect on negative symptoms and cognitive impairments. For the last few decades, discovery efforts have sought nondopaminergic compounds with the aim to effectively treat the broad symptoms of schizophrenia. In this viewpoint, we provide an overview on trace-amine associated receptor-1 (TAAR1), which presents a clinically validated nondopaminergic target for treating schizophrenia and related disorders, with significantly less overall side-effect burden. TAAR1 agonists may also be specifically beneficial for the substance abuse comorbidity and metabolic syndrome that is often present in patients with schizophrenia.
KW - antipsychotics
KW - depression
KW - molecular dynamics
KW - trace amines
KW - treatment-resistant schizophrenia
KW - ulotaront
UR - http://www.scopus.com/inward/record.url?scp=85125299813&partnerID=8YFLogxK
U2 - 10.1021/acsptsci.2c00016
DO - 10.1021/acsptsci.2c00016
M3 - Article
AN - SCOPUS:85125299813
VL - 5
SP - 183
EP - 188
JO - ACS Pharmacology and Translational Science
JF - ACS Pharmacology and Translational Science
SN - 2575-9108
IS - 3
ER -